EW - Edwards Lifesciences Corporation
| Previous Close | 137.57 |
| Open | 137.50 |
| Bid | 0.00 x 1100 |
| Ask | 148.50 x 1100 |
| Day's Range | 135.25 - 137.82 |
| 52 Week Range | 100.20 - 143.22 |
| Volume | 1,002,330 |
| Avg. Volume | 1,376,973 |
| Market Cap | 28.655B |
| Beta | 0.70 |
| PE Ratio (TTM) | 52.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters•3 days ago
Medtronic beats estimates on cardio, diabetes gains
Medtronic Plc topped analysts' estimates for profit in the fourth quarter as it kept a tight lid on costs and upped sales of its heart valves and insulin pumps, offsetting the impact of hurricane damage to production in Puerto Rico. "Relative to nervousness that investors have come to expect around Medtronic's earnings releases, we thought the fourth-quarter print was solid," Evercore ISI analyst Vijay Kumar said. Sales across Medtronic's business units beat analysts' estimates, according to Thomson Reuters I/B/E/S, and the company forecast an adjusted profit of $5.10 to $5.15 per share for fiscal 2019 compared to expectations of $5.14.
- Zacks•3 days ago
Why Is Edwards Lifesciences (EW) Up 1.5% Since Its Last Earnings Report?
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- The Wall Street Journal•6 days ago
[$$] The AI Doctor Will See You Now
The NeuroPace Responsive Neurostimulation System “literally provides peace of mind I never imagined could exist,” she said. Armed with the knowledge of what worked before, the system instructs the implant to stimulate users’ brains to interrupt a seizure at its onset. The innovation is part of a larger phenomenon that has big implications for how we identify and treat disease: the introduction of artificial intelligence to consumer and clinical electronics.
Markit•18 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EW
Market Realist•19 days agoA Look at Abbott Laboratories’ Valuation Multiples
On May 3, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 19.2x, while its PE ratio was 55.7x. This compares to the company’s forward PE and LTM (last-12-months) PE multiples of 20.1x and 57.6x, respectively, in April.
Market Realist•23 days agoNew Product Launches Drive ABT’s Medical Device Business
(Continued from Prior Part)ABT’s Medical Device business In 1Q18, Abbott Laboratories (ABT) registered sales of $7.4 billion, representing YoY (year-over-year) growth of ~16.7%. The company’s Medical Device segment registered strong growth and contributed ~37.0% to the company’s total sales, the highest of all four of its segments. ABT’s Medical Device segment sales came in at ~$2.7 billion in 1Q18. On a reported basis, the segment’s sales growth was ~14.6% on a YoY basis. However, on an organic basis, the segment’s sales increased ~9.4%. ...
Market Realist•23 days agoABT’s Medical Devices Business: A Key Growth Driver
On April 18, Abbott Laboratories (ABT) released its 1Q18 earnings results. The company registered revenues of $7.4 billion, which represents YoY (year-over-year) growth of ~16.7%. These sales results exceeded analysts’ estimates.
Market Realist•24 days agoABT’s Recent Stock Slump: What’s behind the Decline?
On May 2, Abbott Laboratories (ABT) ended trading at a closing price of $58.14 per share. Currently, the stock is trading lower than its 50-day moving average of $59.91 and near its 200-day moving average of $58.22.
Market Realist•24 days agoAnalysts’ Recent Recommendations and Target Price for ABT Stock
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
- Barrons.com•last month
[$$] Positive Analyst Reports on Edwards Lifesciences, Twitter, and PulteGroup
Capital One Financial • COF-NYSE Underperform • Price $97.42 on April 24 by Evercore ISI The bank holding company, which focuses on credit cards, auto loans, savings, and other accounts reported first-quarter 2018 earnings per share from continuing operations of $2.61. Setting aside its restructuring charges and securities gains, we peg core earnings at $2.63, versus our estimate of $2.40 and the consensus estimate of $2.33. Overall, it was a relatively solid quarter, marked by better deposit growth, slightly better loans/receivables growth, and higher interchange fees.
- Thomson Reuters StreetEvents•last month
Edited Transcript of EW earnings conference call or presentation 24-Apr-18 9:00pm GMT
Q1 2018 Edwards Lifesciences Corp Earnings Call
- Associated Press•last month
Edwards Lifesciences, General Dynamics slip; Comcast rises
Stocks that moved substantially or traded heavily Wednesday: Comcast Corp., up 91 cents to $34.26 The cable company had a solid first quarter and offered to buy U.K. broadcaster Sky for $30 billion. Texas ...
- Investor's Business Daily•last month
Edwards CEO Mike Mussallem Driven By Passion For Helping Others
Motivated by a goal to create meaning in his work, Edwards Lifesciences[ticker symb=EW] CEO Mike Mussallem pushed boundaries to follow his passion for helping people live their best lives. In the process, Mussallem and his team have transformed Edwards into the global leader in patient-focused innovations for structural heart disease, as well as critical care and surgical monitoring. Mussallem believes...
- Zacks•last month
Edwards Lifesciences (EW) Q1 Earnings Beat, Revenues Miss
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q1.
- Investor's Business Daily•last month
Premarket: Futures Improve As Boeing, Twitter, 3 Chip Stocks Soar
Premarket trading turned mixed on Wednesday as Boeing, Twitter and Cree gained, Alphabet got an upgrade and Comcast bid $31 billion for Britain's Sky.
- Market Realist•last month
What Drove Edwards Lifesciences’ 1Q18 Earnings?
Japan is the company’s highest growth region outside the United States. Therapy adoption continues to be the major factor driving Edwards’ THVT segment sales in 1Q18. For more on related developments, read Recent Developments at Edwards Lifesciences.
- Market Realist•last month
Edwards Lifesciences Missed Sales Estimates in 1Q18
Edwards Lifesciences Stock Fell on Missed 1Q18 Sales EstimatesEdwards Lifesciences releases 1Q18 results
- InvestorPlace•last month
3 Stocks to Watch on Wednesday: Edwards Lifesciences Corp (EW), Illumina, Inc. (ILMN) and Tesla Inc (TSLA)
Edwards Lifesciences Corp (NYSE:EW) and Illumina, Inc. (NASDAQ:ILMN) reported their quarterly earnings results after hours Tuesday, while Tesla Inc (NASDAQ:TSLA) finds itself in hot waters over a contract dispute. Edward Lifesciences reported its latest quarterly results after hours yesterday. The company announced that the first-quarter global sales of its heart valves, a metric that marks the company’s most important growth driver, increased 2.3% year-over-year to $551.5 million.
- Reuters•last month
Edward Lifesciences' heart valve sales in Europe disappoint, shares fall
Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc. The company's shares fell as much as 8.1 percent in after-market trading as sales of its premium non-invasive device, used to replace diseased aortic valves without open-heart surgery, is its biggest growth driver. "Procedure growth in Europe was double digits this quarter, while our growth was lower due to a year-over-year shift in share to our largest competitor," Chief Executive Officer Michael A. Mussallem said on a call with analysts.
- MarketWatch•last month
Edwards Lifesciences stock drops 8% after forecast misses
Edwards Lifesciences Corp. shares dropped in late trading Tuesday after the company provided a disappointing forecast. The company reported first-quarter earnings of 96 cents a share on sales of $894.8 ...
- Investor's Business Daily•last month
Despite Today's Market, Baozun And Solaredge Technologies Join Sector Leaders
Here’s a list of all the top-rated growth stocks that have just been added to the IBD 50, IBD Big Cap 20, Sector Leaders, Stock Spotlight and IPO leaders.
- Investor's Business Daily•last month
Edwards Lifesciences Tanks After Heart-Valve Sales Lag Expectations
For the first quarter, Edwards reported $937.5 million in adjusted sales and adjusted profit of $1.22 per share.
- CNBC•last month
After-hours buzz: TXN, WYNN, EW & more
See which stocks are posting big moves after the bell.
- Zacks•last month
The Hottest Earnings Charts This Week
All eyes will be on these hot stocks during this busy earnings week.
- CNBC Videos•last month
Edward Life Sciences drops on mixed earnings release
CNBC's Kate Rogers reports on the quarterly earnings for Edward Life Sciences.
